

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

219070Orig1s000

Trade Name: Palsonify tablets, 20 mg and 30 mg

Generic or Proper Name: (paltusotine)

Sponsor: Crinetics Pharmaceuticals Inc.

Approval Date: September 25, 2025

Indication: PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

CENTER FOR DRUG EVALUATION AND RESEARCH

219070Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Integrated Review(s)	X
Product Quality Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

219070Orig1s000

APPROVAL LETTER



NDA 219070

NDA APPROVAL

Crinetics Pharmaceuticals, Inc.
Attention: Kika Teudt, MS
Executive Director, Regulatory Affairs
6055 Lusk Blvd
San Diego, CA 92121

Dear Kika Teudt:

Please refer to your new drug application (NDA) received September 25, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Palsonify (paltusotine) tablets.

This NDA provides for the use of Palsonify (paltusotine) tablets for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling submitted on July 17, 2025, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission **“Final Printed Carton and Container Labeling for approved NDA 219070.”** Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Palsonify (paltusotine) tablets shall be 30 months from the date of manufacture when stored at 20°C to 25°C.

ADVISORY COMMITTEE

Your application for Palsonify was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

REQUESTED ENHANCED PHARMACOVIGILANCE (EPV)

We request that for Palsonify you submit all serious and non-serious domestic and foreign cases of dry age-related macular degeneration, drusen, chorioretinopathy, central serous chorioretinopathy, retinopathy, photophobia, retinal pigment epithelium changes, and retinal pigmentation as 15-day "Alert reports" (described under 21 CFR 314.80(c)(1)) through the 5th year following the initial U.S. approval date.

We also request that you provide a narrative summary including analysis of dry age-related macular degeneration, drusen, chorioretinopathy, central serous chorioretinopathy, retinopathy, photophobia, retinal pigment epithelium changes, and retinal pigmentation as part of your required periodic safety reports (e.g., periodic adverse drug experience report (PADER) required under 21 CFR 314.80(c)(2)), through the 5th year following the initial U.S. approval date.

Your analysis should include interval and cumulative data relative to the date of approval of Palsonify. Your analysis should provide an assessment of causality, with documentation of indication; temporal association; duration of therapy; associated signs and symptoms; detailed information of the ophthalmologic findings at time of the event; additional diagnostic assessment, including baseline ophthalmologic examination (if performed); treatment given for the event; underlying risk factors; confounders, outcome, and dechallenge/rechallenge information.

The goal of this enhanced pharmacovigilance (EPV) plan is to evaluate for possible ocular phototoxicity, corneal dystrophy, and focal retinopathy in the post-marketing setting.

POST APPROVAL FEEDBACK MEETING

New molecular entities qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website⁶.

If you have any questions, contact Jennifer Johnson, Senior Regulatory Project Manager, at (301) 796-2194 or jennifer.johnson@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Lisa B. Yanoff, MD
Deputy Director
Office of Cardiology, Hematology, Endocrinology,
and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert
- Carton and Container Labeling

⁶ <https://www.uspnf.com/>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LISA B YANOFF
09/25/2025 03:43:08 PM